XBiotech (XBIT) Competitors

$2.47 +0.08 (+3.35%)

As of 03:23 PM Eastern

XBIT vs. NGEN, CHRS, AVXL, ORGO, and EDIT

Should you buy XBiotech stock or one of its competitors? MarketBeat compares XBiotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XBiotech include NervGen Pharma (NGEN), Coherus Oncology (CHRS), Anavex Life Sciences (AVXL), Organogenesis (ORGO), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry.

How does XBiotech compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and XBiotech (NASDAQ:XBIT) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

55.7% of XBiotech shares are owned by institutional investors. 5.8% of NervGen Pharma shares are owned by insiders. Comparatively, 30.8% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	N/A	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

In the previous week, NervGen Pharma had 8 more articles in the media than XBiotech. MarketBeat recorded 8 mentions for NervGen Pharma and 0 mentions for XBiotech. NervGen Pharma's average media sentiment score of 0.93 beat XBiotech's score of -1.33 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
NervGen Pharma	Positive
XBiotech	Negative

NervGen Pharma presently has a consensus target price of $18.00, suggesting a potential upside of 389.26%. Given NervGen Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe NervGen Pharma is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NervGen Pharma's return on equity of 0.00% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
XBiotech	N/A	-26.10%	-25.06%

Summary

NervGen Pharma beats XBiotech on 7 of the 9 factors compared between the two stocks.

How does XBiotech compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

In the previous week, Coherus Oncology's average media sentiment score of 0.33 beat XBiotech's score of -1.33 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Coherus Oncology	Neutral
XBiotech	Negative

Coherus Oncology has a net margin of 397.30% compared to XBiotech's net margin of 0.00%. XBiotech's return on equity of -26.10% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
XBiotech	N/A	-26.10%	-25.06%

Coherus Oncology currently has a consensus price target of $8.67, suggesting a potential upside of 446.79%. Given Coherus Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe Coherus Oncology is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Coherus Oncology has higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.80	$168.02M	$1.67	0.95
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by insiders. Comparatively, 30.8% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Coherus Oncology has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Summary

Coherus Oncology beats XBiotech on 11 of the 14 factors compared between the two stocks.

How does XBiotech compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Anavex Life Sciences presently has a consensus price target of $21.33, suggesting a potential upside of 677.17%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 30.8% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Anavex Life Sciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

XBiotech's return on equity of -26.10% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
XBiotech	N/A	-26.10%	-25.06%

In the previous week, Anavex Life Sciences had 1 more articles in the media than XBiotech. MarketBeat recorded 1 mentions for Anavex Life Sciences and 0 mentions for XBiotech. Anavex Life Sciences' average media sentiment score of 0.00 beat XBiotech's score of -1.33 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anavex Life Sciences	Neutral
XBiotech	Negative

Anavex Life Sciences is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

Summary

Anavex Life Sciences beats XBiotech on 7 of the 13 factors compared between the two stocks.

How does XBiotech compare to Organogenesis?

XBiotech (NASDAQ:XBIT) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

55.7% of XBiotech shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 30.8% of XBiotech shares are held by company insiders. Comparatively, 33.0% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Organogenesis had 1 more articles in the media than XBiotech. MarketBeat recorded 1 mentions for Organogenesis and 0 mentions for XBiotech. Organogenesis' average media sentiment score of 1.58 beat XBiotech's score of -1.33 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Overall Sentiment
XBiotech	Negative
Organogenesis	Very Positive

XBiotech has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Organogenesis	-0.84%	9.63%	4.76%

XBiotech has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

Organogenesis has higher revenue and earnings than XBiotech. Organogenesis is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Organogenesis	$564.17M	0.59	$37.03M	-$0.19	N/A

Organogenesis has a consensus target price of $8.50, suggesting a potential upside of 227.55%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts plainly believe Organogenesis is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Organogenesis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Organogenesis beats XBiotech on 12 of the 15 factors compared between the two stocks.

How does XBiotech compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

XBiotech has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. XBiotech's return on equity of -26.10% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
XBiotech	N/A	-26.10%	-25.06%

XBiotech has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.46	-$160.06M	-$1.23	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

Editas Medicine presently has a consensus price target of $5.40, suggesting a potential upside of 101.87%. Given Editas Medicine's stronger consensus rating and higher probable upside, equities analysts clearly believe Editas Medicine is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Editas Medicine had 2 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Editas Medicine and 0 mentions for XBiotech. Editas Medicine's average media sentiment score of 0.65 beat XBiotech's score of -1.33 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Editas Medicine	Positive
XBiotech	Negative

Editas Medicine has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Summary

Editas Medicine beats XBiotech on 9 of the 15 factors compared between the two stocks.

Get XBiotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIT vs. The Competition

Export

Metric	XBiotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$73.33M	$3.35B	$6.33B	$12.33B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-1.82	18.89	20.88	25.51
Price / Sales	N/A	279.14	520.50	73.06
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	0.54	6.90	10.01	7.03
Net Income	-$45.54M	$24.18M	$3.54B	$334.92M
7 Day Performance	-3.80%	0.77%	0.38%	-0.40%
1 Month Performance	-4.56%	-0.38%	-0.02%	1.07%
1 Year Performance	-16.20%	63.37%	35.07%	34.65%

XBiotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIT XBiotech	0.2868 of 5 stars	$2.47 +3.3%	N/A	-19.5%	$75.31M	N/A	N/A	100	Earnings Report Gap Up
NGEN NervGen Pharma	3.8005 of 5 stars	$3.73 -2.6%	$18.00 +382.6%	N/A	$300.75M	N/A	N/A	N/A	Earnings Report Analyst Upgrade
CHRS Coherus Oncology	3.1338 of 5 stars	$1.71 -12.3%	$8.67 +406.8%	+85.0%	$300.72M	$42.17M	1.02	330	High Trading Volume
AVXL Anavex Life Sciences	1.5053 of 5 stars	$3.06 -5.6%	$21.33 +597.2%	-63.5%	$300.26M	N/A	N/A	40	Upcoming Earnings
ORGO Organogenesis	2.7655 of 5 stars	$2.41 +3.4%	$8.50 +252.7%	-21.8%	$299.81M	$564.17M	N/A	950	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIT) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XBiotech (XBIT) Competitors

XBIT vs. NGEN, CHRS, AVXL, ORGO, and EDIT

How does XBiotech compare to NervGen Pharma?

Summary

How does XBiotech compare to Coherus Oncology?

Summary

How does XBiotech compare to Anavex Life Sciences?

Summary

How does XBiotech compare to Organogenesis?

Summary

How does XBiotech compare to Editas Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XBiotech (XBIT) Competitors

XBIT vs. NGEN, CHRS, AVXL, ORGO, and EDIT

How does XBiotech compare to NervGen Pharma?

Do institutionals and insiders hold more shares of NGEN or XBIT?

Which has higher valuation and earnings, NGEN or XBIT?

Does the media refer more to NGEN or XBIT?

Do analysts recommend NGEN or XBIT?

Is NGEN or XBIT more profitable?

Summary

How does XBiotech compare to Coherus Oncology?

Does the media favor CHRS or XBIT?

Is CHRS or XBIT more profitable?

Do analysts recommend CHRS or XBIT?

Which has better valuation and earnings, CHRS or XBIT?

Do insiders & institutionals hold more shares of CHRS or XBIT?

Which has more volatility & risk, CHRS or XBIT?

Summary

How does XBiotech compare to Anavex Life Sciences?

Do analysts prefer AVXL or XBIT?

Do institutionals and insiders hold more shares of AVXL or XBIT?

Which has more volatility and risk, AVXL or XBIT?

Is AVXL or XBIT more profitable?

Does the media refer more to AVXL or XBIT?

Which has better valuation & earnings, AVXL or XBIT?

Summary

How does XBiotech compare to Organogenesis?

Do insiders and institutionals have more ownership in XBIT or ORGO?

Does the media prefer XBIT or ORGO?

Is XBIT or ORGO more profitable?

Which has more risk & volatility, XBIT or ORGO?

Which has better earnings & valuation, XBIT or ORGO?

Do analysts prefer XBIT or ORGO?

Summary

How does XBiotech compare to Editas Medicine?

Is EDIT or XBIT more profitable?

Which has higher earnings and valuation, EDIT or XBIT?

Do analysts rate EDIT or XBIT?

Do insiders and institutionals have more ownership in EDIT or XBIT?

Does the media refer more to EDIT or XBIT?

Which has more volatility and risk, EDIT or XBIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools